0001193125-18-219367.txt : 20180816 0001193125-18-219367.hdr.sgml : 20180816 20180717103604 ACCESSION NUMBER: 0001193125-18-219367 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 675 W. KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 675 W. KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 CORRESP 1 filename1.htm Acceleration Request

Cue Biopharma, Inc.

675 W. Kendall Street

Cambridge, MA 02142

July 17, 2018

VIA EDGAR

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Abigail Jacobs

 

Re: Cue Biopharma, Inc.
     Registration Statement on Form S-1
     File No. 333-225800

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, registrant Cue Biopharma, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) be declared effective at 4:00 p.m., Eastern Time, on Thursday, July 19, 2018, or as soon thereafter as is practicable.

Please direct any questions regarding this request to Mark R. Busch ((704) 331-7440; mark.busch@klgates.com) of K&L Gates LLP. In addition, please notify Mr. Busch when this request for acceleration has been granted.

Sincerely,

/s/ Daniel R. Passeri

Daniel R. Passeri

Chief Executive Officer